Publication | Open Access
Haemoptysis in adults: a 5-year study using the French nationwide hospital administrative database
161
Citations
25
References
2015
Year
Cancer Epidemiology5-Year StudyPatient SafetyPediatricsClinical EpidemiologyHaemoptysis IncidenceRespiratory InfectionInfectious Respiratory DiseasePulmonary MedicinePulmonary DiseaseLung CancerVarious AetiologiesMedicinePublic HealthGeneral EpidemiologyEpidemiologyEmergency MedicineHospital Medicine
Haemoptysis is a serious symptom with various aetiologies. Our aim was to define the aetiologies, outcomes and associations with lung cancer in the entire population of a high-income country.This retrospective multicentre study was based on the French nationwide hospital medical information database collected over 5 years (2008-2012). We analysed haemoptysis incidence, aetiologies, geographical and seasonal distribution and mortality. We studied recurrence, association with lung cancer and mortality in a 3-year follow-up analysis.Each year, ~15 000 adult patients (mean age 62 years, male/female ratio 2/1) were admitted for haemoptysis or had haemoptysis as a complication of their hospital stay, representing 0.2% of all hospitalised patients. Haemoptysis was cryptogenic in 50% of cases. The main aetiologies were respiratory infections (22%), lung cancer (17.4%), bronchiectasis (6.8%), pulmonary oedema (4.2%), anticoagulants (3.5%), tuberculosis (2.7%), pulmonary embolism (2.6%) and aspergillosis (1.1%). Among incident cases, the 3-year recurrence rate was 16.3%. Of the initial cryptogenic haemoptysis patients, 4% were diagnosed with lung cancer within 3 years. Mortality rates during the first stay and at 1 and 3 years were 9.2%, 21.6% and 27%, respectively.This is the first epidemiological study analysing haemoptysis and its outcomes in an entire population. Haemoptysis is a life-threatening symptom unveiling potentially life-threatening underlying conditions.
| Year | Citations | |
|---|---|---|
1997 | 452 | |
Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) | 2014 | 427 |
1995 | 277 | |
1996 | 157 | |
2013 | 141 | |
1991 | 113 | |
1994 | 109 | |
2001 | 99 | |
2001 | 98 | |
2011 | 93 |
Page 1
Page 1